JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cooper, J. R.
Right arrow Articles by Brodie, B. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cooper, J. R.
Right arrow Articles by Brodie, B. B.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Journal of Pharmacology And Experimental Therapeutics, Vol. 112, Issue 1, 55-63, 1954
Copyright © 1954 by American Society for Pharmacology and Experimental Therapeutics


INHIBITORY EFFECTS OF beta-DIETHYLAMINOETHYL DIPHENYLPROPYLACETATE ON A VARIETY OF DRUG METABOLIC PATHWAYS IN VITRO

Jack R. Cooper 1, Julius Axelrod 1, and Bernard B. Brodie 1

1 Laboratory of Chemical Pharmacology, National Heart Institute, National Institutes of Health, Public Health Service, Department of Health, Education, and Welfare, Bethesda 14, Maryland

beta-Diethylaminoethyl diphenylpropylacetate HCl (SKF 525-A) inhibits the enzyme systems in liver slices and homogenates which oxidize the sidechains of pentobarbital, secobarbital, and hexobarbital; dealkylate meperidine, Dibenamine, aminopyrine and its diethyl analogue; deaminate amphetamine; cleave the ether linkage in codeine; and conjugate morphine.

Diphenylpropylacetic acid, a hydrolytic product of SKF 525-A is equally active at a cellular level, though less active in the intact animal.

It is concluded that SKF 525-A inhibits a factor or factors that a diversity of drug enzyme systems possess in common.

Submitted on April 19, 1954




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
P. J. Murphy
The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 1, 1909-1958
Drug Metab. Dispos., January 1, 2008; 36(1): 1 - 5.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
A. H. Conney and J. J. Burns
Metabolic Interactions Among Environmental Chemicals and Drugs: Environmental chemicals that alter microsomal activity may influence the safety and efficacy of drugs
Science, November 10, 1972; 178(4061): 576 - 586.
[Abstract] [PDF]


Home page
ScienceHome page
L. Diamond and H. V. Gelboin
Alpha-Naphthoflavone: An Inhibitor of Hydrocarbon Cytotoxicity and Microsomal Hydroxylase
Science, November 21, 1969; 166(3908): 1023 - 1025.
[Abstract] [PDF]


Home page
ScienceHome page
B. B. Brodie, J. Axelrod, J. R. Cooper, L. Gaudette, B. N. La Du, C. Mitoma, and S. Udenfriend
Detoxication of Drugs and Other Foreign Compounds by Liver Microsomes
Science, April 22, 1955; 121(3147): 603 - 604.
[PDF]


Home page
ScienceHome page
A. Goldin, D. Dennis, J. M. Venditti, and S. R. Humphreys
Potentiation of Pentobarbital Anesthesia by Isonicotinic Acid Hydrazide and Related Compounds
Science, March 11, 1955; 121(3141): 364 - 365.
[PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1954 by the American Society for Pharmacology and Experimental Therapeutics.